Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning

被引:48
|
作者
Cheng, Jun [1 ,2 ,3 ]
Pan, Yi [4 ]
Huang, Wei [4 ]
Huang, Kun [5 ,6 ]
Cui, Yanhai [7 ]
Hong, Wenhui [1 ]
Wang, Lingling [1 ]
Ni, Dong [1 ,2 ,3 ]
Tan, Peixin [4 ]
机构
[1] Shenzhen Univ, Hlth Sci Ctr, Sch Biomed Engn, Natl Reg Key Technol Engn Lab Med Ultrasound,Guan, Shenzhen, Peoples R China
[2] Shenzhen Univ, Med Ultrasound Image Comp MUSIC Lab, Shenzhen, Peoples R China
[3] Shenzhen Univ, Marshall Lab Biomed Engn, Shenzhen, Peoples R China
[4] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China
[5] Indiana Univ Sch Med, Dept Biostat & Hlth Data Sci, Indianapolis, IN 46202 USA
[6] Regenstrief Inst Hlth Care, Indianapolis, IN USA
[7] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Radiol, Guangzhou, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
CT radiomics; immune checkpoint inhibitor-related pneumonitis; lung cancer; machine learning; radiation pneumonitis; RADIOGRAPHIC PATTERNS; RADIOTHERAPY; CHEMORADIOTHERAPY; CHEMORADIATION; PEMBROLIZUMAB; CHEMOTHERAPY; CONCURRENT; MUTATIONS; RISK;
D O I
10.1002/mp.15451
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Consolidation immunotherapy after completion of chemoradiotherapy has become the standard of care for unresectable locally advanced non-small cell lung cancer and can induce potentially severe and life-threatening adverse events, including both immune checkpoint inhibitor-related pneumonitis (CIP) and radiation pneumonitis (RP), which are very challenging for radiologists to diagnose. Differentiating between CIP and RP has significant implications for clinical management such as the treatments for pneumonitis and the decision to continue or restart immunotherapy. The purpose of this study is to differentiate between CIP and RP by a CT radiomics approach. Methods We retrospectively collected the CT images and clinical information of patients with pneumonitis who received immune checkpoint inhibitor (ICI) only (n = 28), radiotherapy (RT) only (n = 31), and ICI+RT (n = 14). Three kinds of radiomic features (intensity histogram, gray-level co-occurrence matrix [GLCM] based, and bag-of-words [BoW] features) were extracted from CT images, which characterize tissue texture at different scales. Classification models, including logistic regression, random forest, and linear SVM, were first developed and tested in patients who received ICI or RT only with 10-fold cross-validation and further tested in patients who received ICI+RT using clinicians' diagnosis as a reference. Results Using 10-fold cross-validation, the classification models built on the intensity histogram features, GLCM-based features, and BoW features achieved an area under curve (AUC) of 0.765, 0.848, and 0.937, respectively. The best model was then applied to the patients receiving combination treatment, achieving an AUC of 0.896. Conclusions This study demonstrates the promising potential of radiomic analysis of CT images for differentiating between CIP and RP in lung cancer, which could be a useful tool to attribute the cause of pneumonitis in patients who receive both ICI and RT.
引用
收藏
页码:1547 / 1558
页数:12
相关论文
共 50 条
  • [41] Using CT Radiomics and Machine Learning to Distinguish Radiotherapy vs. Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer Patients
    Teng, F.
    Wang, P.
    Yu, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E65 - E65
  • [42] Clinical features of immune checkpoint inhibitor-related pneumonitis in older patients with lung cancer receiving immune checkpoint inhibitors-based therapy: a retrospective study
    Jiafan Liu
    Dongmei Zhou
    Na Wu
    Jia Liu
    Xiaonan Wang
    BMC Geriatrics, 25 (1)
  • [43] High-Resolution CT Patterns of Anti-PD1 Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
    Pan, Xiaohuan
    Xie, Xiaohong
    Chen, Xiaojuan
    Chen, Huai
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2024, 48 (06) : 930 - 935
  • [44] Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer
    Cousin, Francois
    Desir, Colin
    Ben Mustapha, Selma
    Mievis, Carole
    Coucke, Philippe
    Hustinx, Roland
    RADIOTHERAPY AND ONCOLOGY, 2021, 157 : 47 - 55
  • [45] Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer: A Retrospective Study
    Cui, Linhong
    Cheng, Kunxiang
    Cui, Mingxin
    Li, Xiaomei
    ONCOLOGY, 2025,
  • [46] Optimizing inpatient care for lung cancer patients with immune checkpoint inhibitor-related pneumonitis using a clinical care pathway algorithm
    Brito-Dellan, Norman
    Franco-Vega, Maria Cecilia
    Ruiz, Juan Ignacio
    Lu, Maggie
    Sahar, Hadeel
    Rajapakse, Pramuditha
    Lin, Heather Y.
    Peterson, Christine
    Leal-Alviarez, Daniel
    Altay, Haider
    Tomy, Sophy
    Manzano, Joanna-Grace Mayo
    SUPPORTIVE CARE IN CANCER, 2024, 32 (10)
  • [47] Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings
    Picasso, Riccardo
    Cozzi, Andrea
    Picasso, Virginia
    Zaottini, Federico
    Pistoia, Federico
    Perissi, Sara
    Martinoli, Carlo
    RADIOLOGIA MEDICA, 2023, 128 (02): : 212 - 221
  • [48] Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings
    Riccardo Picasso
    Andrea Cozzi
    Virginia Picasso
    Federico Zaottini
    Federico Pistoia
    Sara Perissi
    Carlo Martinoli
    La radiologia medica, 2023, 128 : 212 - 221
  • [49] Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer
    Wang, Shiyang
    Tian, Binhe
    Wang, Hanping
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17
  • [50] Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity in Lung Cancer Is Routine Screening Indicated?
    Sun, Lova
    Aggarwal, Charu
    Cohen, Roger B.
    JACC: CARDIOONCOLOGY, 2019, 1 (02): : 193 - 195